Clinical Trials Browser

Phase 2 × Leukemia, Myeloid, Acute × cediranib × Clear all

NCT00475150 2017-02-15

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2 Completed

39 enrolled 9 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute